Linked Data API

Show Search Form

Search Results

1141381
registered interest false more like this
date less than 2019-07-23more like thismore than 2019-07-23
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading MMR Vaccine more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure (a) transparency and (b) accountability in the process of manufacturing the MMR vaccine. more like this
tabling member constituency Gravesham more like this
tabling member printed
Adam Holloway more like this
uin 280999 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-25more like thismore than 2019-07-25
answer text <p>Two Measles, Mumps and Rubella (MMR) vaccines are licensed for use in the United Kingdom: M-M-RVaxPro and Priorix. Both vaccines are on the National Health Service’s routine immunisation schedule. The quality, safety and efficacy of both M-M-RVaxPro and Priorix have been evaluated before they were given a Marketing Authorisation in Europe, and the Marketing Authorisation Holder for each vaccines is legally required to submit periodic safety update reports to the regulator, which are documents intended to provide an evaluation of the risk-benefit balance of a medicinal product at defined time points after its authorisation. The sites at which the products are manufactured are also required to undergo periodic inspections to ensure that they comply with Good Manufacturing Practices. Each batch of vaccines is tested by an official medicines control laboratory (OMCL). OMCL testing is independent of and in addition to the manufacturer’s testing. These procedures ensure that the MMR vaccines available in the UK are safe and efficacious and that the manufacturers/Marketing Authorisation holders are held accountable for their products.</p><p>A European Public Assessment Report (EPAR) for M-M-RVaxPro is available at the following link:</p><p><a href="https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf" target="_blank">https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf</a></p><p>Priorix was approved before public assessment reports were a requirement. The EPAR for M-M-RVaxPro contains a general summary of the manufacturing information that was provided during the assessment process; however, the specific details of the manufacturing process are confidential.</p>
answering member constituency Thurrock more like this
answering member printed Jackie Doyle-Price remove filter
question first answered
less than 2019-07-25T16:38:57.347Zmore like thismore than 2019-07-25T16:38:57.347Z
answering member
4065
label Biography information for Jackie Doyle-Price more like this
tabling member
1522
label Biography information for Adam Holloway more like this
1141380
registered interest false more like this
date less than 2019-07-23more like thismore than 2019-07-23
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading MMR Vaccine: Safety more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps he is taking to maintain and improve pharmacovigilance in relation to the MMR vaccine. more like this
tabling member constituency Gravesham more like this
tabling member printed
Adam Holloway more like this
uin 280998 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-25more like thismore than 2019-07-25
answer text <p>As with all vaccines and medicines, the safety of the Measles, Mumps and Rubella (MMR) vaccine remains under continual review by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA uses all available sources of evidence in pharmacovigilance, including regular review of suspected adverse reactions submitted through the Yellow Card Scheme, data from clinical and epidemiological studies, the medical literature and information from pharmaceutical companies and other worldwide regulatory authorities. The MHRA’s processes and data analysis systems are regularly evaluated to ensure optimal performance in monitoring the safety of vaccines and medicines.</p><p>The balance of benefits and risks of MMR vaccine remains overwhelmingly favourable.</p> more like this
answering member constituency Thurrock more like this
answering member printed Jackie Doyle-Price remove filter
question first answered
less than 2019-07-25T16:35:38.84Zmore like thismore than 2019-07-25T16:35:38.84Z
answering member
4065
label Biography information for Jackie Doyle-Price more like this
tabling member
1522
label Biography information for Adam Holloway more like this
1141255
registered interest false more like this
date less than 2019-07-23more like thismore than 2019-07-23
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Non-surgical Cosmetic Procedures: Children more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what legal duties govern the administering of dermal fillers to people under the age of 18 by non-regulated practitioners. more like this
tabling member constituency North Durham more like this
tabling member printed
Mr Kevan Jones more like this
uin 280927 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-25more like thismore than 2019-07-25
answer text <p>Currently there are no restrictions that limit the administration of dermal fillers on young people under the age of 18 years old.</p><p>The Department is exploring options to introduce age restrictions on access to cosmetic procedures, bringing them in line with legislation on tattoos, teeth whitening and the use of sunbeds. From May 2020 all dermal fillers, irrespective of their composition and intended use, will be regulated as medical devices under Annex XVI of the Medical Device Regulations (EU 2017/745). The new Regulations will significantly improve the quality and safety of dermal fillers.</p><p>The Government is committed to improving the safety of cosmetic procedures through better training for practitioners, and clear information so that people can make informed decisions about their care. The growth in non-surgical treatments increases the need for consumer protection and we are currently working with stakeholders to strengthen the regulation of cosmetic procedures.</p><p>We urge anyone seeking a cosmetic procedure to take the time to find a reputable, insured and appropriately qualified practitioner who is either subject to statutory regulation or on a voluntary register accredited by the Professional Standards Authority.</p>
answering member constituency Thurrock more like this
answering member printed Jackie Doyle-Price remove filter
question first answered
less than 2019-07-25T16:32:36.833Zmore like thismore than 2019-07-25T16:32:36.833Z
answering member
4065
label Biography information for Jackie Doyle-Price more like this
tabling member
1438
label Biography information for Mr Kevan Jones more like this
1140972
registered interest false more like this
date less than 2019-07-22more like thismore than 2019-07-22
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Blood: Contamination more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment has been made of the adequacy of palliative care arrangements and support in place for the victims of the contaminated blood scandal. more like this
tabling member constituency Hornsey and Wood Green more like this
tabling member printed
Catherine West more like this
uin 280426 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-25more like thismore than 2019-07-25
answer text <p>The England Infected Blood Support Scheme (EIBSS) does not currently have direct support provisions for palliative care arrangements. EIBSS does however support beneficiaries to manage their health conditions via discretionary one-off payments.</p><p>Discretionary one-off payments are a form of financial support that beneficiaries and bereaved spouses/partners may apply for to cover the cost of certain essential, health-related items or services.</p><p>Some examples of the one-off payments we support are for home adaptations and repairs to support an individual’s medical conditions, assisting with respite breaks to aid recovery from periods of ill health and supporting the attendance of appointments by providing payments for car repairs and travel costs.</p><p>A full list of the items or services currently supported through EIBSS is available on the NHS Business Services Authority website at the following link:</p><p><a href="https://www.nhsbsa.nhs.uk/support-scheme-members/discretionary-support-scheme" target="_blank">https://www.nhsbsa.nhs.uk/support-scheme-members/discretionary-support-scheme</a></p>
answering member constituency Thurrock more like this
answering member printed Jackie Doyle-Price remove filter
question first answered
less than 2019-07-25T16:01:54.137Zmore like thismore than 2019-07-25T16:01:54.137Z
answering member
4065
label Biography information for Jackie Doyle-Price more like this
tabling member
4523
label Biography information for Catherine West more like this
1140913
registered interest false more like this
date less than 2019-07-22more like thismore than 2019-07-22
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Maternal Mortality more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his policies of the MBRRACE-UK maternal deaths and morbidity statistics 2014-16 showing that (a) Asian women are nearly twice as likely, (b) mixed race women are twice as likely and (c) black women are five times as likely to die during or up to six weeks after pregnancy than white women. more like this
tabling member constituency Newport West more like this
tabling member printed
Ruth Jones more like this
uin 280405 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-25more like thismore than 2019-07-25
answer text <p>The NHS Long Term Plan takes a concerted and systematic approach to reducing health inequalities and addressing unwarranted variation in care. NHS England and NHS Improvement are leading the work through the Maternity Transformation Programme to support maternity services to provide high-quality maternity care for all women.</p><p>Targeted and enhanced continuity of carer can significantly improve outcomes for women from ethnic minorities. The NHS Long Term plan sets out that 75% of black women will receive continuity of carer from midwives by 2024.</p><p>The Department is also funding research to investigate the factors associated with the excess perinatal mortality experienced by black/black British and Asian/Asian British ethnic groups and identify the factors associated with the excess risk of maternal death for black and South Asian women.</p> more like this
answering member constituency Thurrock more like this
answering member printed Jackie Doyle-Price remove filter
question first answered
less than 2019-07-25T16:19:04.357Zmore like thismore than 2019-07-25T16:19:04.357Z
answering member
4065
label Biography information for Jackie Doyle-Price more like this
tabling member
4716
label Biography information for Ruth Jones more like this
1140869
registered interest false more like this
date less than 2019-07-22more like thismore than 2019-07-22
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Mental Health Services: Nottinghamshire more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the (a) availability and (b) waiting times for therapeutic services for mental health conditions in Nottinghamshire. more like this
tabling member constituency Mansfield more like this
tabling member printed
Ben Bradley more like this
uin 280383 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-25more like thismore than 2019-07-25
answer text <p>Information on the availability of therapeutic services for mental health conditions delivered through the Improving Access to Psychological Therapies (IAPT) programme in Nottinghamshire clinical commissioning groups (CCGs)<sup>1</sup> is not collected.</p><p>Information on waiting times for such services in the Nottinghamshire CCGs in 2019 is in the following table.</p><table><tbody><tr><td><p>Month</p></td><td><p>Number of referrals finishing a course of treatment</p></td><td><p>Mean wait to enter treatment<sup>2</sup> (days)</p></td><td><p>Percentage of finishing referrals<sup>3</sup> seen within 6 weeks</p></td></tr><tr><td><p>January 2019</p></td><td><p>1,345</p></td><td><p>24.3</p></td><td><p>83</p></td></tr><tr><td><p>February 2019</p></td><td><p>1,290</p></td><td><p>24.8</p></td><td><p>81</p></td></tr><tr><td><p>March 2019</p></td><td><p>1,510</p></td><td><p>25.3</p></td><td><p>79</p></td></tr><tr><td><p>April 2019</p></td><td><p>1,280</p></td><td><p>27.4</p></td><td><p>76</p></td></tr></tbody></table><p>Source: NHS Digital, IAPT dataset</p><p>Notes:</p><p><sup>1</sup> NHS Bassetlaw CCG, NHS Mansfield and Ashfield CCG, NHS Newark and Sherwood CCG, NHS Nottingham City CCG, NHS Nottingham North and East CCG, NHS Nottingham West CCG and NHS Rushcliffe CCG.</p><p><sup>2</sup> Waiting time to enter treatment is calculated as the number of days between the referral received date and the first attended treatment appointment. Referral received date and the first treatment appointment dates do not necessarily occur in the same month.</p><p><sup>3</sup> In order to finish a course of treatment, a referral must have ended in the month with at least two treatment appointments having been attended in the course of the referral.</p>
answering member constituency Thurrock more like this
answering member printed Jackie Doyle-Price remove filter
question first answered
less than 2019-07-25T16:13:47.043Zmore like thismore than 2019-07-25T16:13:47.043Z
answering member
4065
label Biography information for Jackie Doyle-Price more like this
tabling member
4663
label Biography information for Ben Bradley more like this
1140868
registered interest false more like this
date less than 2019-07-22more like thismore than 2019-07-22
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Prisoners: Synthetic Cannabinoids more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what programmes there are in prisons to provide support for prisoners with synthetic cannabis drug dependency. more like this
tabling member constituency Mansfield more like this
tabling member printed
Ben Bradley more like this
uin 280382 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-25more like thismore than 2019-07-25
answer text <p>In prison, patients presenting with problematic psychoactive substance use are assessed in the same way as other drug users and offered an appropriate range of psychosocial interventions.</p><p>In April 2018, NHS England and NHS Improvement published its updated service specification on ‘Integrated Substance Misuse Treatment Service in Prisons in England’. This is fully aligned to ‘Drug Misuse and Dependence: UK Guidelines on Clinical Management’, which sets out how clinicians should treat people with drug misuse and drug dependence problems.</p><p>The service specification describes a fully recovery orientated, integrated prison substance misuse treatment service, which covers traditional drugs of abuse, psychoactive substances (including synthetic cannabis), illicit abuse of prescribed and over the counter drugs and alcohol.</p><p>This improved substance misuse service offer is now being commissioned across all prisons and secures integration with mental health services so that growing numbers of people in prisons can access services to support their recovery and wellbeing.</p>
answering member constituency Thurrock more like this
answering member printed Jackie Doyle-Price remove filter
question first answered
less than 2019-07-25T16:15:47.693Zmore like thismore than 2019-07-25T16:15:47.693Z
answering member
4065
label Biography information for Jackie Doyle-Price more like this
tabling member
4663
label Biography information for Ben Bradley more like this
1141124
registered interest false more like this
date less than 2019-07-22more like thismore than 2019-07-22
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Health: Disadvantaged more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent assessment he has made of trends in the level of north-south health inequalities. more like this
tabling member constituency Newcastle upon Tyne Central more like this
tabling member printed
Chi Onwurah more like this
uin 280359 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-25more like thismore than 2019-07-25
answer text <p>There are differences in health outcomes relating to socioeconomic status, ethnicity, geographical area and other social factors. Public Health England regularly publishes data on health outcomes, and the wider determinants of health, for the regions of England in the Public Health Outcomes Framework at the following link:</p><p><a href="https://fingertips.phe.org.uk/profile/public-health-outcomes-framework" target="_blank">https://fingertips.phe.org.uk/profile/public-health-outcomes-framework</a></p><p>The Government is working to improve the quality of people’s lives across the whole country. The Prevention Green Paper sets out proposals to secure five extra years of health, independent life by 2035 and reducing the gap between the rich and poor. The NHS Long Term Plan also commits to narrowing health inequalities over the next five and 10 years. We want everyone to have the same opportunity to have a long and healthy life wherever they live and whatever their circumstances.</p><p><strong> </strong></p><p><strong> </strong></p>
answering member constituency Thurrock more like this
answering member printed Jackie Doyle-Price remove filter
question first answered
less than 2019-07-25T16:06:22.32Zmore like thismore than 2019-07-25T16:06:22.32Z
answering member
4065
label Biography information for Jackie Doyle-Price more like this
tabling member
4124
label Biography information for Chi Onwurah more like this
1140960
registered interest false more like this
date less than 2019-07-22more like thismore than 2019-07-22
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Metamizole: Spain more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps the Government is taking to raise awareness of the potential side-effects of the drug metamizole among UK citizens and tourists in Spain. more like this
tabling member constituency Liverpool, Wavertree more like this
tabling member printed
Luciana Berger more like this
uin 280290 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-25more like thismore than 2019-07-25
answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
answering member constituency Thurrock more like this
answering member printed Jackie Doyle-Price remove filter
grouped question UIN
280288 more like this
280289 more like this
question first answered
less than 2019-07-25T16:07:40.807Zmore like thismore than 2019-07-25T16:07:40.807Z
answering member
4065
label Biography information for Jackie Doyle-Price more like this
tabling member
4036
label Biography information for Luciana Berger more like this
1140958
registered interest false more like this
date less than 2019-07-22more like thismore than 2019-07-22
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Metamizole: Spain more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if he will have discussions with his Spanish counterpart on the effect of dispensing metamizole to (a) UK and (b) Spanish residents in Spain. more like this
tabling member constituency Liverpool, Wavertree more like this
tabling member printed
Luciana Berger more like this
uin 280289 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-25more like thismore than 2019-07-25
answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
answering member constituency Thurrock more like this
answering member printed Jackie Doyle-Price remove filter
grouped question UIN
280288 more like this
280290 more like this
question first answered
less than 2019-07-25T16:07:40.76Zmore like thismore than 2019-07-25T16:07:40.76Z
answering member
4065
label Biography information for Jackie Doyle-Price more like this
tabling member
4036
label Biography information for Luciana Berger more like this